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Abstract
Background: Foot problems associated with Systemic Sclerosis (SSc)/Scleroderma have been reported to be both
common and disabling. There are only limited data describing specifically, the mechanical changes occurring in
the foot in SSc. A pilot project conducted in preparation for this trial confirmed the previous reports of foot related
impairment and reduced foot function in people with SSc and demonstrated a link to mechanical etiologies. To-
date there have been no formal studies of interventions directed at the foot problems experienced by people with
Systemic Sclerosis. The primary aim of this trial is to evaluate whether foot pain and foot-related health status in
people with Systemic Sclerosis can be improved through the provision of a simple pressure-relieving insole.
Methods: The proposed trial is a pragmatic, multicenter, randomised controlled clinical trial following a completed
pilot study. In four participating centres, 140 consenting patients with SSc and plantar foot pain will be randomised
to receive either a commercially available pressure relieving and thermally insulating insole, or a sham insole with
no cushioning or thermal properties. The primary end point is a reduction in pain measured using the Foot
Function Index Pain subscale, 12 weeks after the start of intervention. Participants will complete the primary
outcome measure (Foot Function Index pain sub-scale) prior to randomisation and at 12 weeks post
randomisation. Secondary outcomes include participant reported pain and disability as derived from the
Manchester Foot Pain and Disability Questionnaire and plantar pressures with and without the insoles in situ.
Discussion: This trial protocol proposes a rigorous and potentially significant evaluation of a simple and readily
provided therapeutic approach which, if effective, could be of a great benefit for this group of patients.
Trial registration number: ISRCTN: ISRCTN02824122
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Background
Systemic sclerosis (SSc)/Scleroderma is a connective tis-
sue disease characterised by excessive collagen produc-
tion resulting in microvascular and macrovascular
damage, fibrosis of the skin and internal organs [1-3].
The prevalence of SSc in the UK is 8.21 per 100,000 [4]
with an age of onset as early as the second decade [5].
The young age of the disease onset is reflected in the
high societal costs. In 1997 the direct and indirect costs
of SSc in the United States was $1.5 billion [6].
Foot problems associated with SSc include: Raynaud’s
phenomenon, which sometimes can progress to tissue
loss/ulceration, subcutaneous calcinosis, skin thickening,
callus formation, tendonopathy, foot ulcers, joint space
narrowing, bone demineralization, joint subluxation,
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joint margin erosions and degenerative changes [7-9].
Arthropathy is also common in patients with SSc and is a
major determinant of disability [8].
There are parallels between some of the foot symptoms
seen in SSc and those in people with rheumatoid arthritis
(RA). In RA, inflammatory arthropathy leads to joint
damage, which in turn causes increased plantar pressures
and altered pressure distribution. Plantar pressure has
been reported to be higher under metatarsophalangeal
(MTP) joints that are eroded and where fibro-fatty pad-
ding displacement has occurred, resulting in values
exceeding normal limits [10,11]. Plantar fat-pad atrophy
in RA patients also contributes further to altered normal
plantar pressure distribution [12,13]. People with SSc
have also been shown to suffer from bone erosions [7-9]
and subcutaneous fat atrophy [14,15], which could lead
to plantar fat-pad atrophy, consequently increasing plan-
tar foot pressures.
Abnormal plantar foot pressures are widely noted as a
risk factor for ulceration in people with diabetes and this
additive relationship has also been established in diseases
closer in nature to SSc, such as RA [16,17]. The conse-
quences of the musculoskeletal changes noted above, on
plantar pressures have not been studied in SSc.
In related diseases, high plantar pressures and pro-
longed duration of loading are associated with pain dur-
ing walking [11,18]. However, the mechanisms by which
foot pain is increased in people with SSc [7,19] have not
been investigated. It is well established that pain is com-
mon in SSc and is the strongest predictor of physical
functioning in SSc patients [20]. In other diseases where
foot pain is associated with increased plantar pressure,
simple treatments such as cushioned insoles have been
shown to be highly effective [21]. Again, the effective-
ness of these simple and inexpensive treatments has not
been investigated in SSc.
The presence of both abnormal plantar pressures and
plantar foot pain in patients with SSc has been con-
firmed in a pilot study conducted by the investigating
team.
Pilot study
A pilot project [22] investigated 14 people with SSc who
provided data on foot pain, impact of pain on foot health
status and high resolution plantar pressure data. SSc pain
and pressure data were compared with a further 14
healthy controls matched for age and gender.
Patients with SSc reported worse foot pain on a 100 mm
visual analogue pain scale (VAPS), SSc mean 36.8 mm
(SD = 25.7) compared with a mean of 2.2 mm (SD = 4) in
healthy controls. Pressure data demonstrated intense loca-
lisation of plantar pressures to discrete areas in close
proximity to the MTP joints.
The SSc group had markedly higher forefoot pressures
across a range of pressure variables when compared
with the control group. Peak plantar pressures and pres-
sure time integrals were particularly high over the first
MTP joint.
To address the possible concern that people with SSc
have significant systemic complications that may be
considered to overwhelm the impact of relatively minor
foot complaints, patients were asked explicitly whether
reducing foot pain would improve their quality of life.
Thirteen out of fourteen respondents indicated explicitly
that they would derive benefit from interventions
intended to reduce their foot symptoms.
In conclusion, the literature, the pilot study results
and the patients themselves indicate that there is a clear
need for studies investigating the effect of SSc on plan-
tar pressures and plantar foot pain. Furthermore, if inex-
pensive and simple interventions known to work in
other diseases offer an effective treatment option, then





To compare foot pain in participants using a commer-
cially available pressure-relieving insole, to those using
the sham insole (control), 12 weeks after randomisation.
Secondary objective
To determine the impact of insoles on patient-reported
foot disability and function
To assess the impact of the insoles on scleroderma
health status
Exploratory objective
To explore the relationship between pain, and the distri-
bution and magnitude of plantar pressures (Leeds site
only)
To provide further validation data on the newly devel-
oped SSc Quality of Life Scale
Design
Pressure and pain In Systemic Sclerosis/SCleroderma
(PISCES) is a pragmatic, phase III, multicentre, rando-
mised, controlled trial.
Recruitment and randomisation
Recruitment of the 140 participants will occur over 20
months to allow completion of the twelve-week follow-up
within the 24-month time frame of the clinical phase of the
study. All potentially suitable patients attending the rele-
vant departments’ outpatient’s clinics will be approached
and provided with a verbal explanation of the trial and a
copy of the ethically approved patient information sheet.
Arrangements will be made prior to the commencement of
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the trial to stream potentially suitable patients into early
trial clinics. Alternatively, patients identified by other
means such as waiting lists or upon review of case records,
will receive a letter and the ethically approved patient infor-
mation sheet from their consultant rheumatologist, which
will provide comprehensive information and invite them to
participate in the study. Those who express an interest to
participate will be invited to contact their local research
team to make an appointment to discuss the trial further.
Informed written consent will be obtained from the
patients.
Each participant will undergo a pre-trial eligibility
screen and baseline assessment prior to randomisation
and insole allocation. Randomisation will take place
after baseline measures have been recorded to eliminate
selection bias
Those participants who meet the eligibility criteria will
be randomly allocated to receive one of two interven-
tions. The participants will be randomised on a 1:1 basis
to receive either the active intervention (simple pres-
sure-relieving insole) or the control (sham insole). Stra-
tified block randomisation will be used to ensure
intervention groups are well-balanced for gender and
centre.
Randomisation will be performed centrally using a
24-h, automated randomisation system based at the
Leeds Clinical Trials Research Unit,
Follow-up
Participants will wear the insoles for 12 weeks and then
return for a 12-week follow-up visit prior to exiting the
trial. Mid-trial telephone follow-ups will be performed at
6 weeks post randomisation to identify whether the parti-
cipant has any problems with tolerability, to establish
compliance with the intervention and encourage comple-
tion of the patient diary. During the 12-week follow-up
visit, participants will be asked to complete the same
questionnaires as at baseline, supervised by a member of
authorised trial staff blinded to insole allocation, and will
be required to return their 12-week diary. Participants
unable to attend at precisely 12-weeks will be eligible for
follow-up between week 11 and week 14. For those parti-
cipants who cannot attend during this window, question-
naires will be posted to the participants’ home address by
the participating site. Following the 12-week assessment
visit the participants will exit the trial, and any continua-
tion of care will be followed up by the relevant NHS
department at the participating centre, as per local policy.
A clinical decision as to the appropriateness of providing
the participants with the alternative pair of insoles upon
trial exit will be made on an individual basis.
In addition, the participants from the Leeds centre will
be offered further assessment of bare foot plantar pres-
sures and in-shoe plantar pressures at baseline. Additional
written informed consent will be obtained prior to
assessment.
The trial design is summarized in the trial flow dia-
gram (Figure 1)
Setting & subjects
A total of 140 participants with SSc will be recruited
from four centres in the UK which specialise in treatment
and study of SSc. Sixty participants will be recruited by
the Leeds Teaching Hospitals NHS Trust, Leeds; 25 par-
ticipants from the Salford Royal Hospitals NHS Trust,
Manchester; 40 participants from the Royal Free Hamp-
stead NHS Trust, London; and 15 participants from the
Newcastle Upon Tyne Hospitals NHS Foundation Trust,
Newcastle.
Potential participants 18 years of age or over will be
screened for enrollment. To be included in the trial,
participants must meet the following eligibility criteria:
Inclusion criteria
1. Consultant diagnosis of SSc or a positive diagnosis of
SSc (ARA/ACR 1980 criteria [23]) defined by
Major criterion:
• Proximal diffuse (truncal) sclerosis (skin tight-
ness, thickening, non-pitting induration)
Minor criteria:
• Sclerodactyly (only fingers and/or toes),
• Digital pitting scars or loss of substance of the
digital finger pads (pulp loss), and/or
• Bilateral basilar pulmonary fibrosis.
(The patient should fulfill the major criterion or two
of the three minor criteria unless a consultant diagnosis
has been made).
2. Patient-reported plantar foot pain.
3. Willing and able to comply with the intervention
schedule for 12 weeks.
4. Able to provide written informed consent to partici-
pate in the study.
Exclusion criteria
Patients with the following characteristics are considered
ineligible for this study:
1. Disease overlap syndromes (overlap with Inflamma-
tory Arthritis (IA)/RA)
2. History of any lower limb bone or joint orthopaedic
surgery within the past 12 months
3. Diagnosis of diabetes
4. Loss of protective sensation on the plantar surface
of the foot
5. Current use of prescribed or over-the-counter con-
toured or made-to-measure insoles/orthoses
6. History of any clinically significant disease or major
disorder that in the opinion of the treating clinician or
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Figure 1 Trial flow diagram.
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Chief Investigator would not be conducive to trial
participation
Details of all eligible potential participants will be
recorded, along with detailed reporting of inclusion/
exclusion to guard against recruitment bias.
Intervention
Treatment insole
The active intervention to be tested is a commercially
available pressure relieving insole (Prothotic™ Duoform,
Algeo’s Ltd, Merseyside UK, cost £8.55). The insoles are
composed of 4 mm thick polyurethane cushioning and a
2 mm Plastazote layer, which provides cushioning and
thermal insulation. While a standard insole is being
used for consistency, this is a relatively generic product
and the insole being evaluated would represent a variety
of similar products available on the open market.
Sham insole
The sham intervention used in the control arm will consist
of a 1 mm thick regenerated leather-board base with a
thin (< 1 mm) plastazote cover. The sham intervention
will provide a physical insole similar in appearance to the
active intervention insole and will look identical once
placed in the participants’ shoes, but will not offer cush-
ioning or alter the plantar foot pressures. Minimal to none
thermal insulating properties are expected, given the thin-
nest possible plastazote layer achieved in manufacture.
The randomised insole (active or sham) will be fitted
into the participants’ shoes by the attending clinicians.
To standardise the delivery of the intervention (i.e. fit-
ting the insoles) all of the practitioners involved in its
delivery will undergo a standardised training programme
prior to the start of recruitment.
Participants will be advised to wear the insoles as much
as possible during the day for the next 12 weeks. Partici-
pants will be provided with a diary providing clear written
information regarding the use of, and care of their insoles,
including what to do if they become lost or damaged. To
monitor intervention compliance and to identify other
confounders (e.g. pain and medication), the participants
will also be asked to document compliance with insole use
in the diary. The diary will also be used to detail the intake
of medication specifically for foot pain
Blinding
Although the active and sham insoles will look identical
when placed in the shoes, it is recognised that protec-
tion of blinding may not be possible on all occasions.
The following controls will be employed to maintain the
blinding of the trial as far as is reasonably practicable:
The sham insole (control) will be similar in appearance
to the active insole, and will look identical in appearance
once placed in the participants’ shoes. The key staff at
site involved with the trial will remain blinded to the
intervention allocation during the study. This will be
achieved by having different teams of therapists responsi-
ble for randomising participants to those responsible for
administering the assessment questionnaires.
The majority of outcome measures are patient-
reported and should not be influenced by clinician
knowledge of the insole allocation. The trial participants
will be provided with minimal opportunity to meet and
discuss interventions with other participants.
Primary and secondary outcome measures
The primary outcome measure is a reduction in foot pain
as measured by the pain subscale of the Foot Function
Index (FFI) [24]. The FFI is a validated, self-assessment
questionnaire, which was developed to measure the
impact of foot pathology in people with RA and which
has now been used in a wide range of rheumatic diseases.
The pain subscale of the FFI uses visual analogue scales
(VAS) to measure the severity of pain using a Likert-type
response set with anchors describing “no pain” and
“worst pain imaginable”, with a mean score derived.
Secondary outcome measures will include participant
reported pain and disability as reported via the Manche-
ster Foot Pain and Disability Questionnaire [25], sclero-
derma function and health status using the Scleroderma
Health Assessment Questionnaire (S-HAQ) [26], and
quality of life using the newly developed Scleroderma
Quality of Life Questionnaire which is an exploratory
endpoint due to lack of full validation of this question-
naire to-date.
Objective gait laboratory data will be obtained at the
lead centre in Leeds. Plantar foot pressures will be
recorded using the Novel EMED-ST (Novel-GmbH,
Munich, Germany) pressure platform at baseline to
obtain high-resolution measures of pressure and force
distributions. Pressures at the shoe/insole interface will
also be obtained separately, using the Novel Pedar in-
shoe system. The following measures will be reported:
maximum mean pressure at forefront of the foot (five
metatarsal heads) (kPa), maximum mean pressure at
heel of the foot (kPa), contact area at forefront of the
foot (cm2), contact area at heel of the foot (cm2), gait
velocity (metres per second), cadence (steps per minute)
and step/stride length (cm).
Assessments
Foot Function Index Pain Subscale, S-HAQ, Manchester
Foot Pain and Disability Score and Scleroderma QoL
will be completed by participants as part of their base-
line and 12 week follow-up assessments.
A Foot Pain Map will be completed at baseline to
identify the specific area of pain.
The modified Rodnan Skin Score (mRSS) will be cal-
culated for each participant as a measure of disease
severity at baseline. The mRSS is a validated measure
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for dermal skin thickness used universally in rheumatol-
ogy for this purpose [27,28]. The most widely used ver-
sion is the 17 site assessment system, which will be
employed in this trial and undertaken as part of the
baseline assessments.
Participant diaries, instructions on how to complete
them and instructions for ongoing use of insoles will be
given to the participants prior to them leaving the clinic.
Exploratory measures of foot plantar pressures will be
carried out at baseline (after randomisation and insole
allocation) on consenting participants at the Leeds cen-
tre only. The plantar foot pressure measurements are
undertaken in two stages:
Stage 1: Bare foot plantar pressures (measured by
EMED-ST pressure platform (hi-res))
Three representative steps, for each foot, are recorded
from the participant walking barefoot over the platform
using a common ‘two-step start’ protocol. The EMED
platform will allow analysis of a range of pressure, force,
area and temporal variables at high resolution (4 sensors/
cm2). This will enable a detailed model of the interaction
of the participants’ foot with the supporting surface to be
developed which will inform our characterisation of the
baseline effects of the disease. It is not possible however
to investigate the effect of the therapy using the platform
system, thus requiring a second stage of pressure study.
Stage 2: In-shoe plantar pressures measured by the
Pedar System (Novel GmbH, Munich, Germany).
A flexible pressure-measuring insole is inserted into the
footwear and the participant undertakes two straight line
walks of approximately eight metres, generating approxi-
mately 20 representative steps. The trial intervention
(active or sham insole) on a separate measure is then
added to the footwear, the pressure measuring insole is
added over the top, and the process repeated. Randomisa-
tion on sequence of measures (with/without insole first)
will be employed via a computer generated randomisation.
The in-shoe pressure measurements are derived using a
capacitance based matrix of 99 sensors per insole which
again generate a range of force, pressure, area and tem-
poral variables characterising the loading of the plantar
surface of the foot. Measures are derived automatically
within software for pre-determined areas of the foot. After
collection but with the participant still present, data are
evaluated graphically within the software to ensure the
integrity of the measures. Once checked the quantitative
data is output to a CSV delimited spreadsheet file for sub-
sequent processing.
Power calculation/sample size consideration
The trial is powered to detect change in the primary out-
come, the Foot Function Index pain subscale. The mini-
mal important difference for FFI pain subscale has been
reported to be 12 mm [29]. We have decided to use a
conservative minimal important difference between inter-
vention arms of 15 mm.
To detect a difference between groups of 15 mm, with a
standard deviation of the response variable = 25.7 (from
our pilot data; other published studies providing FFI pain
data with insole use have also reported standard deviations
of between 20 and 27); alpha = 0.05 and power set at 90%,
63 participants per group are needed. To allow for a 10%
drop out rate, a total of 140 participants will be
randomised.
Statistical analysis
The primary outcome of the change in VAS FFI pain sub-
scale between baseline and 12 weeks will be compared
between intervention groups using Analysis of Covariance
adjusting for baseline pain score, centre and gender.
Model assumptions will be checked and if found to be
violated data will be transformed prior to analysis or a
non-parametric analysis method will be used. Summary
statistics of the foot pain score at baseline and week 12
will be presented for the overall pain component as well as
each individual pain question. Similar methods will be
used for other study questionnaires.
Objective gait analysis
All analyses will be according to intention to treat; no
interim analyses are planned due to the short follow-up
period and the safe nature of the intervention.
Discussion
The project has been driven from the outset by unmet
participant need. First identified as a problem area by
participants in the Leeds Connective Tissue Disease
Outpatients clinic, the trial was piloted formally with
full consultation with people with SSc. While the design
of the project has been led methodologically by the
CTRU, patient consultation has been undertaken
throughout the design phase, and formal patient repre-
sentation will be undertaken through the trial steering
committee.
Although the primary outcome is a patient-reported
outcome, the two types of insole (active and sham) are
as similar as possible in appearance to conceal the allo-
cation from both patient and clinician and to avoid bias
and attrition as far as possible. Randomisation will be
performed centrally at the CTRU thus ensuring alloca-
tion concealment and minimising any imbalance
between the two trial arms.
The trial evaluates a simple intervention carrying mini-
mal risk to participants. There are no invasive tests and
no exposure to ionising radiation or other environmental
hazards. To maximise participant protection the protocol
includes a rescue provision for participants who are
unable to tolerate their allocated intervention, or for
whom the intervention causes other physical problems.
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The 12 weeks follow-up in this trial will allow time for
the period of adaptation to the therapy and for the eva-
luation of its effects. Follow-up in previous studies
investigating the effects of orthotic therapy on foot pain
varies, but it has been shown that significant decreases
in pain can be achieved after 3 months with the therapy
[23]. Longer term follow-up might be warranted in
future depending on the results of this trial and the
impact of any results on future treatment protocols.
This trial will have immediate and direct health bene-
fits for patients with SSc, extending the knowledge of
practitioners to effectively manage foot pain in people
with SSc. The trial will establish definitively the burden
of foot problems in people with SSc and will determine
the effectiveness of a simple and inexpensive insole in
reducing plantar pressures and ameliorating symptoms.
Ethical consideration
Ethical and governance approval for this trial has been
obtained from the Leeds West Ethics Committee (ref
10/H1307/83) and the Leeds Teaching Hospitals NHS
Trust respectively. The trial progress is monitored by an
independent Trial Steering Committee.
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